Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

The EGFR family is among the most investigated receptor protein-tyrosine kinase groups
owing to its general role in signal transduction and in oncogenesis. This family consists of …

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …

EGFR mutations account for the majority of druggable targets in lung adenocarcinoma. Over
the past decades the optimization of EGFR inhibitors revolutionized the treatment options for …

The emergence of acquired resistance against targeted drugs remains a major clinical
challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an …

Background MNNG HOS transforming gene (MET) exon 14 mutations in lung cancer,
including exon 14 skipping and point mutations, have been attracting the attention of …

Purpose: Resistance to third-generation EGFR inhibitors including osimertinib arises in part
from the C797S mutation in EGFR. Currently, no targeted treatment option is available for …

Abstract Epidermal Growth Factor Receptor (EGFR), a transmembrane tyrosine kinase
receptor, belongs to the ErbB receptor family, also known as HER1 or ErbB1. Its abnormal …

Objectives Oncogenic HER2 mutations are present in 2–4% of lung adenocarcinomas, but
the relevant clinical trials are unsatisfactory. The novel HER2 inhibitor poziotinib was …

Epidermal growth factor receptor (EGFR), a transmembrane glycoprotein that mediates
cellular signaling pathways involved in cell proliferation, angiogenesis, apoptosis, and …